Navigation Links
A new anti diabetic drug on the anvil

India leads the top 10 countries estimated to have the highest number of diabetics in 2000 and 2030, with China and the US following closely. Type II Diabetes, one of the most common chronic diseases globally, is fast gaining // epidemic proportions throughout the world, with pathological manifestations including obesity, hypertension, hyperlipidemia and cardiovascular diseases. Since diabetes causes significant morbidity and mortality due to long-term micro and macro vascular complications, new drugs are required to combat it.

Glenmark Pharmaceuticals has recently filed for Phase I clinical trials for GRC 8200, its leading DPP-IV inhibitor compound, with the Medicines and Healthcare Products Regulatory Agency [MHRA] in the U.K. The dipeptidylpeptidase IV [DPP-IV] target is associated with glucose dependent insulin secretion and peripheral insulin resistance. While no DPP-IV inhibitor has been approved for marketing till date, among the scientific community DPP-IV inhibitors are expected to offer significant potential for being the therapy of choice, once approved.

The Phase I study will be conducted by Parexel U.K., a leading global CRO. The Phase I study is expected to be completed in February 2006 and will be conducted using single and multiple oral doses on healthy volunteers. The objective of this study is to assess the safety and bioavailability of GRC 8200 in humans. Pre-clinical studies have demonstrated GRC 8200 to be many times more potent than competing DPP-IV inhibitors. The compound is highly bioavailable and safe, displaying significant reduction in glucose excursion on oral glucose challenge. Pre-clinical studies have also demonstrated that GRC 8200 has the potential of being a long-acting compound with high selectivity to the DPP-IV target over DPP-II, VIII and IX.

Glenn Saldanha, Managing Director and CEO of Glenmark, states “We have a very aggressive timeline and hope to be the fourth to market with GRC 8200 in the DPP-IV class. We expect GRC 8200 to be launched on the US market in 2010.”
'"/>




Related medicine news :

1. Gastrointestinal ills more common in diabetics
2. Pollution- hazardous for diabetics
3. New treatment for diabetics
4. Breast screening among diabetic women
5. Needle free future for diabetics
6. Care for footwear not required diabetic patients
7. Nightlights could ward diabetic blindness
8. Gene variant foretells diabetic neuropathy
9. Protein in diabetic neuropathy treatment
10. New target for antidiabetic agents identified
11. Study links diabetics to increased risk of urinary tract infections
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to ... Care Medicine will host industry leaders for the annual spring Convention & Expo, ... the industry adapt to the issues currently affecting urgent care and on-demand healthcare. ...
(Date:4/28/2017)... ... 2017 , ... Bill Howe started his sewer and drain company in 1980 ... joined the team, the Bill Howe brand was born and they began cultivating their ... back to the San Diego community in which they worked, lived and were raising ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA ... region. Côté has 20+ years of experience within the beauty industry, ranging from ... an array of high-end cosmetic brands, retail brands and outlets in Canada and ...
(Date:4/28/2017)... CA (PRWEB) , ... April 28, 2017 , ... NuevaCare, ... cities as diverse as Millbrae, Burlingame, and Palo Alto, is proud to announce information ... interested persons to bookmark and read organized content on topics such as home care ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Deutsche Bank Securities ... in Boston, Massachusetts on Wednesday, ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .  The webcast will ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
Breaking Medicine Technology: